Lowy D R, Kirnbauer R, Schiller J T
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1994 Mar 29;91(7):2436-40. doi: 10.1073/pnas.91.7.2436.
Genital human papillomavirus (HPV) infection is a common sexually transmitted disease that at the present time is not effectively controlled or treated. Many infections are inapparent and transient. However, some HPV infections result in persistent lesions that in some cases undergo carcinogenic progression. A subset of genital HPVs, designated high-risk types, are preferentially associated with high-grade dysplasias and carcinomas. About 90% of cervical cancers contain high-risk HPV DNA, most often HPV16. Development of a subunit vaccine against high-risk genital HPVs is a desirable and, it appears, an increasingly feasible long-term goal. The viral E6 and E7 oncoproteins are selectively maintained and expressed in progressed HPV tumors and could potentially be targets for therapeutic vaccines. The L1 major virion structural proteins have recently been shown to self-assemble into virus-like particles when expressed in insect cells. These particles might serve as the basis for a prophylactic vaccine to prevent genital HPV infection.
生殖器人乳头瘤病毒（HPV）感染是一种常见的性传播疾病，目前尚未得到有效控制或治疗。许多感染是不明显且短暂的。然而，一些HPV感染会导致持续性病变，在某些情况下会发生致癌进展。一部分生殖器HPV，被指定为高危型，优先与高级别发育异常和癌症相关。约90%的宫颈癌含有高危HPV DNA，最常见的是HPV16。开发一种针对高危生殖器HPV的亚单位疫苗是一个理想的、而且似乎越来越可行的长期目标。病毒E6和E7癌蛋白在进展期HPV肿瘤中被选择性地维持和表达，可能成为治疗性疫苗的靶点。最近研究表明，L1主要病毒体结构蛋白在昆虫细胞中表达时能自组装成病毒样颗粒。这些颗粒可能作为预防性疫苗的基础，以预防生殖器HPV感染。
